Cardiff Oncology, Inc. (CRDF)
0.9073
-0.02
(-2.23%)
USD |
NASDAQ |
Oct 23, 16:00
0.9006
-0.01
(-0.74%)
After-Hours: 20:00
Cardiff Oncology Net Income (Quarterly) : -9.232M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.232M |
| March 31, 2026 | -12.34M |
| December 31, 2025 | -7.216M |
| September 30, 2025 | -11.26M |
| June 30, 2025 | -13.94M |
| March 31, 2025 | -13.43M |
| December 31, 2024 | -11.79M |
| September 30, 2024 | -11.86M |
| June 30, 2024 | -11.78M |
| March 31, 2024 | -10.01M |
| December 31, 2023 | -9.337M |
| September 30, 2023 | -9.731M |
| June 30, 2023 | -11.15M |
| March 31, 2023 | -11.22M |
| December 31, 2022 | -8.697M |
| September 30, 2022 | -8.571M |
| June 30, 2022 | -10.44M |
| March 31, 2022 | -10.99M |
| December 31, 2021 | -9.442M |
| September 30, 2021 | -6.913M |
| June 30, 2021 | -6.757M |
| March 31, 2021 | -5.179M |
| December 31, 2020 | -6.597M |
| September 30, 2020 | -4.496M |
| June 30, 2020 | -4.124M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.089M |
| December 31, 2019 | -4.242M |
| September 30, 2019 | -4.142M |
| June 30, 2019 | -4.125M |
| March 31, 2019 | -3.905M |
| December 31, 2018 | -4.159M |
| September 30, 2018 | -3.770M |
| June 30, 2018 | -3.747M |
| March 31, 2018 | -4.786M |
| December 31, 2017 | -2.57M |
| September 30, 2017 | -4.292M |
| June 30, 2017 | -8.046M |
| March 31, 2017 | -10.000M |
| December 31, 2016 | -8.548M |
| September 30, 2016 | -10.19M |
| June 30, 2016 | -10.20M |
| March 31, 2016 | -10.26M |
| December 31, 2015 | -7.381M |
| September 30, 2015 | -2.736M |
| June 30, 2015 | -10.18M |
| March 31, 2015 | -7.174M |
| December 31, 2014 | -4.683M |
| September 30, 2014 | -5.375M |
| June 30, 2014 | -1.077M |
| March 31, 2014 | -3.190M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.104M |
| Total Expenses (Quarterly) | 9.336M |
| EPS Diluted (Quarterly) | -0.1351 |
| Enterprise Value | 28.09M |
| Gross Profit Margin (Quarterly) | -113.5% |
| Profit Margin (Quarterly) | -8.88K% |
| Earnings Yield | -65.09% |
| Normalized Earnings Yield | -65.08 |